The present invention provides for compositions and methods for administering one or more UDP compound, alone or in combination with another hematopoietic progenitor cell mobilizing compound (for example, but not limited to G-CSF), to mobilize hematopoietic progenitor cells for transplant or other purposes. The methods of the invention may be particularly advantageous as applied to improve the stem cell yield in so-called “poor mobilizing” patients.

Methods for inducing CD8+ T cells to express a CD62L.sup.hiCD44.sup.lo naïve-like phenotype are provided. One embodiment provides a pharmaceutical composition containing CD8+ T cells induced to express a CD62L.sup.hiCD44.sup.lo naïve-like phenotype and optionally an excipient. The CD8+ T cells can be induced by contacting them with an effective amount of a MEK1/2 inhibitor. An exemplary MEK1/2 inhibitor is Selumetinib. The induced CD8+ cells can be used to treat cancer, reduce tumor burden, or treat infections in a subject in need thereof.

Methods for inducing CD8+ T cells to express a CD62L.sup.hiCD44.sup.lo naïve-like phenotype are provided. One embodiment provides a pharmaceutical composition containing CD8+ T cells induced to express a CD62L.sup.hiCD44.sup.lo naïve-like phenotype and optionally an excipient. The CD8+ T cells can be induced by contacting them with an effective amount of a MEK1/2 inhibitor. An exemplary MEK1/2 inhibitor is Selumetinib. The induced CD8+ cells can be used to treat cancer, reduce tumor burden, or treat infections in a subject in need thereof.

The present disclosure is directed to methods for assessing the severity and progression of a SARS-CoV2 infection in a subject using cell-free DNA (cfDNA). The present disclosure is further directed to methods for assessing tissue damage as a result of SARS-CoV2 infection. In addition, the present disclosure provides methods for treating a SARS-CoV2 infection in a subject. Finally, the disclosure also provides methods for detecting a microbial co-infection of a subject suffering from a SARS-CoV2 infection.

The present disclosure is directed to methods for assessing the severity and progression of a SARS-CoV2 infection in a subject using cell-free DNA (cfDNA). The present disclosure is further directed to methods for assessing tissue damage as a result of SARS-CoV2 infection. In addition, the present disclosure provides methods for treating a SARS-CoV2 infection in a subject. Finally, the disclosure also provides methods for detecting a microbial co-infection of a subject suffering from a SARS-CoV2 infection.

A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.

Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

The present invention pertains to a compound, particularly ovatodiolide, for use in preventing or treating an infection of a virus, including a hepatitis virus, an influenza virus, a herpes simplex virus, an enterovirus, a rotavirus, a dengue virus, a poxvirus, a human immunodeficiency virus, an adenovirus, a coronavirus, an arenavirus, a measles virus, a retrovirus and a norovirus, particularly SARS-COV-2. Also provided are the method for preventing or treating a virus infection using the compound, and the pharmaceutical composition or composition comprising the compound.

The present invention pertains to a compound, particularly ovatodiolide, for use in preventing or treating an infection of a virus, including a hepatitis virus, an influenza virus, a herpes simplex virus, an enterovirus, a rotavirus, a dengue virus, a poxvirus, a human immunodeficiency virus, an adenovirus, a coronavirus, an arenavirus, a measles virus, a retrovirus and a norovirus, particularly SARS-COV-2. Also provided are the method for preventing or treating a virus infection using the compound, and the pharmaceutical composition or composition comprising the compound.